Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

A restful night’s sleep is vital to a healthy lifestyle but an Indiana physician said most Americans are not getting enough ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Wall Street’s major averages ended mostly lower on Friday, as market participants have been keeping an eye on the highly anticipated meeting between Donald Trump and Vladimir Putin. However, the S&P ...

Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.